AllergoOncology: Generating a canine anticancer IgE against the epidermal growth factor receptor
To the Editor:
Cancer immunotherapy with antibodies has revolutionized clinical oncology, giving hope for patients with cancer. Among these, cetuximab, a mouse-human chimeric antibody, targeting the human epidermal growth factor receptor (EGFR), 1 inhibits growth signaling and mediates antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) E5,2 of tumor cells. Harnessing T H 2 immune responses against cancer is a subject in the emerging field of ''AllergoOncology,'' taking advantage of the high capacity of IgE to trigger immune reactions against cancer.
3 Unlike Fcg-receptors, all Fcε-receptors are activating. 3 Because fewer than 1 in 10 anticancer drugs translate from murine preclinical studies to human clinical trials, 4 we focused on dogs (Canis lupus familiaris) with spontaneously occurring cancer as potential efficacy models. Mammary carcinomas and osteosarcomas in dogs and humans frequently overexpress EGFR. 4, 5 Also, human and canine immune systems are highly similar, 3 rendering canine clinical trials a promising alternative to rodent experiments.
We previously developed a caninized cetuximab IgG, ''can225IgG, '' 6 which here we engineered into cetuximab IgE, ''can225IgE-l,'' retaining the exact epitope specificity, but with the canine l-and ε-constant domains. Can225IgE-l was cloned using a ligation-free cloning technique E13 and expressed in Expi293F cells on the basis of our previously published method 7 (Fig 1, A; see this article's Methods section in the Online Repository at www.jacionline.org). The affinity-purified can225-IgE-l had an apparent molecular mass of 235 kDa (Fig 1, B) and was correctly assembled (Fig 1, C and D) with low amounts of free chains.
We confirmed antibody specificity to recombinant human EGFR by Western blot (Fig 1, E) , to native EGFR on human A431 breast cancer cells (Fig 1, F) , to P114 canine mammary carcinoma (Fig 1, G) and D17 canine osteosarcoma (Fig 1, H) cells, but no binding to EGFR-negative CHO K1 (control) cells (Fig 1, I) .
Next, we assessed FcεRI expression on effector cell lines. Both human promonocytic U937 and canine monocytic/macrophagelike DH82 cells showed moderate to high FcεRI expression (Fig 1, J and K) . Furthermore, canine MPT-1 mast cells showed relatively lower FcεRI expression (Fig 1, L) compared with RBL-SX38 rat basophilic leukemia cells transfected with human tetrameric FcεRI (Fig 1, M) . Because no cross-reactive antibody for canine FcεRII (CD23) was available, we evaluated CD23 expression on canine effector cell lines by RT-PCR. We observed a more than 1000-fold higher relative CD23 expression by MPT-1, compared with DH82 cells (Fig 1, N) . The can225IgE-l antibody bound to Fcε receptors on U937 cells (Fig 2, A) , DH82 cells (Fig 2, B) , and MPT-1 (Fig 2, C) cells.
Having shown tumor target specificity and recognition of immune effector cells by can225IgE-l, we next used a tumor cell killing assay E4 to quantify immune-mediated tumor cell killing by can225IgE-l via flow cytometry. Tumor cells killed by cytotoxicity (ADCC) and phagocytosis (ADCP) were counted separately (for gating strategy, see Fig E1, A, in this article's Online Repository at www.jacionline.org). We first used human A431 as cancer target cells, U937 as effector cells, and human and dog cetuximab IgG E5 and IgE versions. Both cetuximab IgG and IgE showed high tumor cell killing potential, mostly via ADCC (Fig 2, D) mediated by effector cells.
Canine IgE shows a 33 times weaker binding strength to the human FcεRI compared with human IgE. Accordingly, can225IgE-l-triggered tumor killing with human effector cells was significantly lower than that triggered by human cetuximab-IgE (Fig 2, E) . None of the antibodies had a significant effect on the ADCP of tumor cells (see Tables E1 and E3 in this article's Online Repository at www.jacionline.org).
We furthermore evaluated whether can225IgE-l could activate canine effector cells (Fig 2, F and G ; Table E1 ). In a time-dependent manner (Fig E1, K) significantly higher levels of ADCC by canine DH82 macrophages compared with can225IgG (Fig 2, F) . Conversely, and in agreement with previous studies, E7,8 can225IgG was significantly superior to IgE with regard to triggering tumor cell ADCP (see Table E4 in this article's Online Repository at www.jacionline.org).
In addition, we investigated the effects of an approach using 50:50 can225IgG and can225IgE-l at the same total antibody amount as samples treated with individual antibodies. Combinational treatment performed comparable tumor cell ADCC to that by can225IgE-l alone, but significantly better ADCC than that by can225IgG alone. ADCP was lower than that triggered by can225IgG, but higher than in can225IgE-l monotherapy (Fig 2, F) .
Overall, can225IgE-l mediated higher levels of total tumor cell killing compared with those mediated by can225IgG alone. Moreover, combining can225IgG and can225IgE-l was significantly superior to each isotype alone (Fig 2, G; see Table E2 and Table E4 in this article's Online Repository at www.jacionline.org).
Similarly, we evaluated the cytotoxic killing potency of can225IgE-l by MPT-1 canine mast cells against A431 and measured specific tumor cell killing (Fig 2, H) . Although ADCP assessment by flow cytometry was not possible in this experimental setting due to cell clumping, we could indeed confirm mast cell-mediated ADCC by fluorescence microscopy (Fig 2, I ). Such effector functions may be due to can225IgE-l specifically binding to IgE receptors (FcεRI on RBL-SX38 cells, Fig 2, J) and canine CD23, expressed on transfected CHO K1 cells (Fig 2, K) .
Therefore, we established an in vitro system for quantification and side-by-side comparison of anticancer ADCC/ADCP triggered by cetuximab IgG, IgE, and their canine counterparts. Unlike in humans where k:l light chains are expressed in a ratio of 2:1, the average k:l ratio in dogs is 1:9.
E11 Hence, we engineered can225IgE-l. Because canine IgE is able to bind human FcεRI, we could demonstrate dose-dependent binding of can225IgE-l on human U937 (Fig 2, A) in addition to the expected binding to canine FcεRI on DH82 and MPT-1 cells (Fig 2, B and C) . Furthermore, we showed that DH82 Expression vector construct (A), can225IgE-l on a silver-stained protein gel (B), and western blot developed with antidog IgE (Fc) (C) and with antidog light chain (D). Binding of can225IgE-l to human EGFR by Western blot (E) and to EGFR on human and canine target cell lines using EGFR-negative cell line CHO K1 for control (F-I). FcεRI expression on human and canine effector cell lines (J-M) and relative CD23 expression of MPT-1 canine mast cells compared with DH82 monocytic/macrophage-like cells, normalized to beta-actin expression (N). CMV, Cytomegalovirus; HER-2, epidermal growth factor receptor 2; PE, phycoerythrin; SV40, simian vacuolating virus 40.
macrophages express low levels of CD23 (Fig 1, N) , but high levels of functional FcεRI (Fig 1, K) , which is likely responsible for triggering IgE-mediated tumor cell killing (Fig 2, F and G) , comparable to that mediated by human U937 monocytic effector cells. Using the canine DH82 macrophages, we were able to generate a species-relevant in vitro model system with which we confirmed the tumoricidal potencies of our canine antibodies, can225IgG or can225IgE-l, alone, or combined.
It has been observed that human IgG triggers considerable levels of ADCP, whereas IgE mainly elicits ADCC by human monocytes/macrophages. E7,8 We observed the same in the dog system and we also report significantly higher total tumor cell killing induced by IgE. We furthermore anticipated that IgE could act complementary to IgG, through using different Fc-receptors on effector cells. Coincubation with can225IgG and can225IgE-l exerted higher tumor cell death, than did IgG or IgE treatment alone (Fig 2, F) . Finally, we also demonstrate that can225IgE-l is able to trigger specific ADCC against EGFR 1 tumor cells by canine MPT-1 mast cells (Fig 2, H and I) .
Additional studies are needed to further evaluate these promising results with other IgG or IgE effector cells. 3, 9 This study presents the first in vitro functionally active canine anticancer IgE antibody for future clinical studies in dog cancer patients that may offer new options in cancer immunotherapy. Micro RNAs are required for Langerhans cell, skin-and lung-resident macrophage ontogeny
To the Editor: Epidermal Langerhans cells (LCs), skin-residing dendritic cells (DCs), control both induction of adaptive immunity and immune tolerance in skin and are involved in the development of skin diseases, including skin allergy and atopic dermatitis. Recent lineage-tracing studies have uncovered that rather than from bone marrow (BM)-derived DC precursors, adult mouse LCs are derived from embryonic yolk sac-derived macrophages and fetal liver monocytes.
1 Like epidermal LCs, tissue-resident macrophages (TRMs) also follow unique patterns of ontogeny, deriving from embryonic yolk sac-derived macrophages or fetal liver monocytes, and they play critical roles in tissue development, homeostasis, and the development of some diseases. In contrast to the infiltrating monocytes, which are recruited via extravasation from blood vessels after local inflammation initiation and then produce inflammatory mediators but do not persist after the resolution of inflammation, the TRMs proliferate locally and are involved in the inflammation initiation or inducing tolerance, and then back to the quiescence following remission, and persist locally (see additional references in this article's Online Repository at www.jacionline.org). TRMs in the skin and lungs have been shown to have an impact on the progression and resolution of allergic inflammation, such as allergic contact dermatitis 2 and asthma. 3 Up to now, a few genes have been identified to regulate LC and TRM embryonic development, including cytokines IL-34 and GM-CSF, which are required for the development of LCs and lung-resident alveolar macrophages (AMs), respectively, as well as TGF-b, which is essential for both LC and lung AM ontogeny and homeostasis 4 (see additional references in this article's Online Repository). MicroRNAs (miRNAs), a class of evolutionarily conserved small noncoding RNAs, negatively regulate the expression of protein-coding genes and are involved in immune cell development and function. 5 However, it is totally unknown whether miRNAs are involved in LC and TRM ontogeny.
The RNase III enzyme DICER is essential for the processing of mature and functional miRNAs; therefore, its deletion provides a genetic test for miRNA function. The conditional inactivation of DICER in the BM and the thymus has indicated the requirement for miRNA activity in regulatory T-cell and natural killer T-cell development. 5 Interestingly, deletion of DICER in BM myeloid lineage by LysM Cre does not affect monocyte and macrophage development or even tumorassociated macrophages. 6 Recently, colony-stimulating factor 1 receptor (CSF1R) Cre reporter (called Csf1r
Cre ) was used to fate map embryonic TRM and LC precursor development. 7 To study the role of miRNAs in the embryonic development of LCs and TRMs, we crossed Csf1r
Cre mice with Dicer fl/fl mice to generate Csf1r
Cre Dicer fl/fl conditional knockout (cKO) mice, in which DICER is deficient in the CSF1R-expressing cells including LCs, TRMs, and monocytes. 7 As expected, the expression of all tested miRNAs in BM-derived macrophages (gating strategy shown in Fig E1, A, in this article's Online Repository at www.jacionline.org) from DICER cKO mice was completely diminished or dramatically reduced (Fig 1, A) . We first compared the frequencies of epidermal RESULTS AND DISCUSSION Affinity purification of can225IgE-l In contrast to previous reports, E1 we did not succeed in purifying can225IgE-l by Protein A affinity columns. This might be possibly due to 2 IgE isoforms in dogs, IgE1 having a high affinity toward Staphylococcal Protein A and IgE2 not at all binding to protein A.
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ADCC and ADCP assay using EGFR-CHO K1 as target cells
The EGFR-negative CHO K1 cell line was used as control target cells. These cells were not recognized by can225IgE-l (Fig  1, I) . Consequently, CHO K1 cells were also not attacked by the human monocytic U937 cells (Fig E1, C and D) or the canine monocytic/macrophage-like DH82 cells (Fig E1, E and F) .
Phenotypical characterization of DH82 and MPT-1 cells DH82 cells appeared as single, round cells in culture and showed only 1 distinct population in flow cytometry scatter plots ( Fig E1, B) ; 77.4% of DH82 cells were positive for CD16 (DMFI, 713), 99.9% for CD14 (DMFI, 12922), and 72.2% for CD80 (DMFI, 2797) (Fig E1, G-I ).
DH82 cells transform over time from a monocyte-to a macrophage-like phenotype, associated with changes in CD14 and CD80 surface marker expression. E3 However, both CD14 and CD80 expression levels, as well as morphology and the uniform population in flow-cytometric scatter plots, identified a monocytic phenotype, E3 which was advantageous because the 3-color flow-cytometric assay had been established for monocytes. E4 
METHODS
For proof-of-concept studies in the field of comparative immuno-oncology and AllergoOncology, the recombinant canine IgE antibody can225IgE-l was developed against EGFR, which has 95% amino acid sequence homology and 92% identity among humans and dogs. E5 The antibody was expressed in a transient expression system and characterized with respect to correct assembly, EGFR specificity, and binding to IgE receptors FcεRI and CD23. In addition, the functionality of can225IgE-l was evaluated in a flow-cytometric ADCC and ADCP assay using human and canine monocyte-like cells, as well as canine mast cells as effectors against EGFR-overexpressing tumor and EGFR-negative control cells, as described below.
Cell lines, antibodies, and antigens
Cell lines. Human monocytic cell line U937 (CRL-1593.2), human epidermoid carcinoma cell line A431 (CRL-1555), canine osteosarcoma cell line D17 (CCL183), canine monocyte/macrophage-like cell line DH82 (CRL-10389), and Chinese hamster ovary cell line CHO K1 (CCL-61) were purchased from the American Type Culture Collection (Manassas, Va). Canine mammary carcinoma cell line P114 was a kind gift of G. Rutteman, University of Utrecht (Utrecht, The Netherlands). Canine mast cell line MPT-1 E6 was a kind gift of Prof. H. Matsuda, Tokyo University of Agriculture and Technology (Tokyo, Japan). U937 was cultured in RPMI 1640 GlutaMAX medium (Gibco, Thermo Fisher Scientific, Waltham, Mass) supplemented with 10% (v/v) FBS (Gibco, Thermo Fisher Scientific) and 100 U/mL penicillin and 100 mg/mL Streptomycin (Gibco, Thermo Fisher Scientific). A431 was grown in high glucose (4.5 g/L) Dulbecco modified Eagle medium (DMEM) GlutaMAX medium (Gibco, Thermo Fisher Scientific), supplemented with 10% FBS and 100 U/mL penicillin and 100 mg/mL streptomycin. D17 was grown in Minimum Essential Medium (MEM) GlutaMAX (Gibco, Thermo Fisher Scientific), augmented with 10% FBS and 100 U/mL penicillin and 100 mg/mL streptomycin. P114 was cultured in DMEM/F-12 GlutaMAX (Gibco, Thermo Fisher Scientific) media supplemented with 10% FBS and 100 U/mL penicillin and 100 mg/mL streptomycin. DH82 was cultured in low glucose (1 g/L) DMEM GlutaMAX medium (Gibco, Thermo Fisher Scientific), supplemented with 10% FBS and 100 U/mL penicillin and 100 mg/ mL streptomycin. MPT-1 was grown in alpha-MEM GlutaMAX medium (Gibco, Thermo Fisher Scientific), supplemented with 10% FBS and 100 U/ mL penicillin and 100 mg/mL streptomycin. CHO K1 was grown in Ham's F-12 Nutrient Mix GlutaMAX (Gibco, Thermo Fisher Scientific), augmented with 0% FBS and 100 U/mL penicillin and 100 mg/mL streptomycin. All cells were maintained in a humidified incubator at 378C under a 5% CO 2 atmosphere.
Antibodies. Cetuximab (Erbitux) was purchased from Merck (Darmstadt, Germany). Rituximab (MabThera) was used as human IgG isotype control and was purchased from Roche (Basel, Switzerland 
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Antigens. Recombinant human EGFR (extracellular domain) was purchased from ACROBiosystems (cat# EGR-H5222). Recombinant human epidermal growth factor receptor 2 (extracellular domain) was produced inhouse by Lec-1 cells, E10 which were a kind gift of D. Leahy from Johns Hopkins University School of Medicine (Baltimore, Md).
Cloning of can225IgE-l
Cetuximab heavy-chain variable region sequence was fused with the canine immunoglobulin epsilon constant sequence (NCBI GenBank: AAA56797.1). Cetuximab light-chain variable region sequence was fused with the canine lambda (because of its higher prevalence in dogs than in humans). E11 The light-chain constant sequence (NCBI Ref Seq: XP_013963655.1) can be found among the coding sequences in Table E5 . The final sequences were synthesized by GeneArt in Strings DNA format (Thermo Fisher Scientific) and cloned into pCR-Blunt vector using Zero Blunt PCR Cloning Kit (Thermo Fisher Scientific). Coding sequences were recloned into pVitro1-hygro (Invivogen, San Diego, Calif) using a ligation-free polymerase incomplete primer extension cloning method adapted from Dodev et al. E12 All primers used for polymerase incomplete primer extension cloning are listed in Table E6 . The pVitro-hygro-can225-IgE-l construct was then transformed into Escherichia coli Top10 (Thermo Fisher Scientific). Correct clones were verified using Sanger sequencing.
Production and purification of can225IgE-l Can225IgE-l was produced according to Ilieva et al E13 in human Expi293F cells using the pVitro1 vector (Fig 1, A) and purified with a custom affinity column using the € AKTA FPLC system from GE Healthcare Life Sciences (Chicago, Ill). Custom anti-dog IgE column was made by crosslinking 1 mg goat anti-dog IgE (cat# NB7343, Novus Biologicals, Littleton, Colo) to HiTrap Protein G HP column (GE Healthcare Life Sciences) in the presence of 50-fold molar excess disuccinimidylsuberate (Sigma-Aldrich, St Louis, Mo). PBS, pH 7.4, was used as binding and washing buffer. Bound can225IgE-l was then eluted with 0.1 M glycine (pH 2.5) followed by immediate pH neutralization using 1 M tris-HCl, pH 8.0.
PAGE and immunoblots
PAGE was run using tris-glycine-based 4% to 20% Mini-PROTEAN TGX gels (Bio-Rad Laboratories, Hercules, Calif), Laemmli loading buffer, and molecular weight markers Spectra Multicolor High Range Protein Ladder (Fig 1, B-D) and PageRuler Plus Prestained Protein Ladder (Fig 2, A) from Thermo Fisher. The gels were loaded with 0.5 mg can225IgE-l/canine IgE isotype or 1 mg recombinant human EGFR/recombinant human epidermal growth factor receptor 2/BSA and the proteins were subsequently detected either by silver staining or by immunoblot. Blocking and antibody dilutions were performed with 5% (w/v) skimmed milk powder dissolved in tris buffered saline, pH 7.2, 1 0.1% (v/v) tween-20. Canine IgE was detected using horseradish peroxidase-labeled goat anti-dog IgE (cat# 7346, Novus Biologicals) at 1:5000 for 1 hour, or by 0.5 mg/mL can225IgE-l for 2 hours at room temperature. Blots were developed with Clarity Western enhanced chemiluminescence substrate (Bio-Rad) using the VersaDoc Imaging System (BioRad). Light chains were detected using 0.5 mg/mL anti-dog light-chain antibody (cat# A40-124A, Bethyl Laboratories) followed by alkaline phosphatase-labeled donkey anti-goat IgG detection antibody (cat# A16008, Thermo Fisher) at 1:2000, and subsequently visualized using 1-Step NBT/ BCIP substrate solution (Thermo Fisher).
Determination of the molecular mass
The apparent molecular mass of can225IgE-l on silver-stained PAGE was determined using GelAnalyzer 2010a software (Istvan Lazar and Dr Istvan Lazar). Spectra Multicolor High Range Protein Ladder (Thermo Fisher Scientific) was used as a reference.
Flow-cytometric binding assays
Specificity testing. A431, D17, P114, and CHO K1 cells were detached using Accutase solution (Sigma-Aldrich). A total of 3 3 10 5 cells/tube were stained with 10 mg/mL can225IgE-l (or isotype control) for 30 minutes on ice followed by 10 mg/mL fluorescein isothiocyanate (FITC)-labeled goat anti-dog IgE (cat# NB7345, Novus Biologicals) for 30 minutes on ice in a light-protected environment. The cells were analyzed on a 3-laser FACSCanto II flow cytometer (BD Biosciences, Franklin Lakes, NJ).
FcεRI staining of effector cells. DH82 and MPT-1 (3 3 10 5 per test) were stained with 10 mg/mL phycoerythrin-labeled anti-mouse FcεRI (clone MAR-1) (cat# 12-5898-83, eBioscience, Santa Clara, Calif) or appropriate isotype controls. U937 and RBL-SX38 cells (3 3 10 5 per test) were stained with 10 mg/mL anti-human FcεRI (clone CRA-1) (cat# 14-5899-82, eBioscience, Santa Clara, Calif), or mouse IgG2b isotype control, detected by 10 mg/mL FITC-labeled goat anti-mouse IgG (cat# F0479, DAKO, Agilent Technologies, Santa Clara, Calif).
Fc-binding assay. U937, DH82, and MPT-1 cells (3 3 10 5 per test) were incubated with can225IgE-l at different concentrations (1, 2.5, 5 , and 10 mg/ mL) for 30 minutes at 378C. Bound can225IgE-l was detected with 10 mg/mL FITC-labeled goat anti-dog IgE.
Receptor-specific binding of can225IgE-l. RBL-SX38 or canine CD23-transfected CHO K1 cells (3 3 10 5 per test) were incubated with 10 mg/ mL can225IgE-l for 30 minutes. Following a washing step, bound can225IgE-l was detected with 10 mg/mL FITC-labeled goat anti-dog IgE.
Characterization of DH82 cells. DH82 cells (passages 16-27, 3 3 10 5 per test) were stained with APC-labeled anti-human CD14 clone T€ uk4 (cat# MHCD1405, Thermo Fisher)/FITC-labeled anti-human CD16 (clone LNK16) (cat# MA1-19611, Thermo Fisher)/phycoerythrin-labeled anti-mouse CD80 (clone 16-10A1) (cat# 12-0801-82, eBioscience), or the respective controls. Cells were incubated with antibodies at concentrations according to the manufacturer's instructions for 30 minutes and washed before acquisition.
Real-time PCR analysis of canine CD23 expression
Total RNA of 5 3 10 6 DH82 and MPT-1 was isolated using the RNeasy Mini Kit (cat# 74104, Qiagen, Venlo, The Netherlands) and transcribed using the SuperScript II reverse transcriptase (cat# 18064022, Thermo Fisher) along with oligo(dT) 12-18 primers (cat# 18418012, Thermo Fisher) according to the manufacturer's instructions. Real-time PCR was performed using SYBR Green PCR Master Mix (cat# 4309155, Applied Biosystems, Thermo Fisher). Primers for canine CD23: forward: CCCAGAGCTTGAACGAGAGAA, reverse: TCCTCGCCGAAGTAGTAGCAC, as described by Amagai et al.
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Primers for beta-actin: forward: ATTGCCGACAGGATGCAGAA, reverse: GCTGATCCACATCTGCTGAA. RT-PCR analysis was performed using 3 biological replicates (and 3 technical replicates of each biological replicate).
3-Color flow-cytometric ADCC and ADCP assay
Flow-cytometric ADCC/ADCP assays were performed using the method described by Bracher et al. E4 A431 tumor cells were prestained with 5 mM of the green fluorescent dye carboxyfluoresceinsuccinimidyl ester for 10 minutes, 18 hours before the experiment. The tumor cells (70000/test) were incubated with 5 mg/mL antibody solution in assay buffer (RPMI 1640 GlutaMAX 12% (v/v) FBS) at 378C for 30 minutes. Next, 210,000 U937 cells/tube were coincubated with the tumor cells at 378C for 2.5 hours. Following the incubation, U937 were labeled with APC-conjugated anti-human CD89 antibody (cat# 354106, BioLegend, San Diego, Calif) . Dead cells were detected using the blue fluorescent DNA dye 49,6-diamidino-2-phenylindole (cat# D1306, Thermo Fisher), few seconds before acquisition on the FACSCanto II.
When using DH82 or MPT-1 as effector cells, both tumor and effector cells were stained with cell-tracking dyes 18 hours in advance to the treatment antibodies and coincubation: Tumor cells were prestained with carboxyfluoresceinsuccinimidyl ester (as described earlier), whereas DH82 and MPT-1 were prestained with 1 mM CellTrace Far Red (Thermo Fisher) for 10 minutes. Because effector cells were already prelabeled in this case, no CD89 staining was needed to tag the cells after the coincubation of the tumor and effector cells. All assays were performed at least 3 times using 3 technical replicates per condition. Data were analyzed using FlowJo V10.0.7 (Flow Jo LLC, Ashland, Ore).
Fluorescence microscopy
Samples were prepared as described in the 3-color flow-cytometric ADCC and ADCP assay section using MPT-1 canine mast cells and A431 tumor cells. Fifteen microliter of the nonfixed cell suspension was mounted on a glass slide immediately after 49,6-diamidino-2-phenylindole staining, and fluorescence microscopy pictures were recorded 20 minutes within mounting using an Axioplan 2 fluorescent microscope (Carl Zeiss Microscopy GmbH, Jena, Germany) with a 203 air objective.
Generation of canine CD23-expressing CHO K1 cells CHO K1 cells were transfected with pcDNA3.3-TOPO (Thermo Fisher) containing the coding sequence of canine CD23 (back-translated from the amino acid sequence disclosed under GenBank accession number AAN20273.1) using Lipofectamine 3000 (Thermo Fisher) according to the manufacturer's instructions. Forty-eight hours after transfection, 1 mg/mL G418 (cat# CP11.3, Carl Roth) was added and selection pressure was maintained over 3 weeks before proceeding to IgE-binding assays.
Statistical analyses
Statistical analyses were carried out using GraphPad Prism v5.00 for Windows (GraphPad Software, Inc, La Jolla, Calif). (Table E3 and Table E4 ), we used 2-way ANOVA with Bonferroni posttest (phagocytosis and cytotoxicity). To compare the total killing induced by the antibodies (Fig 2, E and G, and Fig E1, D and F) , we used 1-way ANOVA followed by Tukey multiple comparison test. Statistical significances are defined as *P < .05, **P < .01, and ***P < .001.
FIG E1.
Gating strategies, ADCC and ADCP control assays, and phenotypical characterization of effector cells. Gating strategy in flow-cytometric ADCC and ADCP assays (A) and DH82 cell characterization (B). ADCC-and ADCP-triggering potency (C) and total tumor cell killing (D) induced by can225IgE-l compared with other antibodies in a negative control assay using U937 as effector and EGFR-negative CHO K1 as target cells. ADCC-and ADCP-triggering potency (E) and total tumor cell killing (F) induced by can225IgE-l compared with other antibodies in a negative control assay using DH82 as effector and EGFR-negative CHO K1 as target cells. DH82 cell characterization in regard of CD16 (G), CD14 (H), and CD80 (I) expression, pointing toward a monocyte-like phenotype. Negative control experiment to Fig 2, K: nontransfected (parental) CHO K1 did not bind can225IgE-l (J). Evaluating IgE-mediated tumor cell killing over time confirmed previous literature reporting 2.5 hours as the optimal incubation time (K). CFSE, Carboxyfluoresceinsuccinimidyl ester; FSC-A, forward scatter-area; ns, nonsignificant; SSC-A, side scatter-area. Total killing 32% 6 2.9% 32% 6 3.6% 67% 6 3.8% 32% 6 1.6% 74% 6 2.6% 34% 6 1.9% 82% 6 3.1%
Depicted are mean values 6 SDs in percent of the total number of tumor cells in the sample. n 5 9 in all groups except combinational treatment with dog IgG and IgE isotype control and can225IgG1IgE, where n 5 6. ISO, Isotype control antibody; PBS, phosphate buffered saline, mock-treated control. 
